Now I have all the evidence I need. Let me verify one more thing — whether the paper explicitly states that large LMs were NOT fine-tuned:

The paper says in Section 3.2: "To further enhance **small-model** capabilities, we applied three parameter-efficient fine tuning(PEFT) methods...to each **small LLM**." (line 144). And Figure 3 shows large LMs with only ICL bars (their LoRA column shows "-").

Similarly for radiology: only Florence 2 and Qwen 2.5-VL are described under fine-tuning setup (lines 282-283), with no corresponding fine-tuning description for Med-Flamingo or LLaVA-Med.

Now I have everything needed for the consolidated review.

## Summary

This paper evaluates small language models (≤3B parameters) against larger domain-adapted models on clinical text summarization and radiology report generation, using both in-context learning and parameter-efficient fine-tuning. It claims that after LoRA fine-tuning, small LMs outperform large medical LMs, and introduces a "Collapse Analysis" framework to identify a safety threshold at ~1B parameters.

## Strengths

- **Well-motivated research question.** Evaluating whether small, deployable models can match large models for clinical summarization is practically important for privacy, cost, and on-premise deployment, as the paper correctly motivates in §1 and §2.
- **Multi-dimensional evaluation.** The paper uses BLEU, ROUGE-L, BERTScore, and MEDCON (UMLS concept overlap) to capture syntactic, semantic, and clinical fidelity (§3, "Evaluation Metrics"), providing a more nuanced comparison than any single metric.
- **Prompt sensitivity mitigation.** Zero-shot results in Table 2 are averaged across five instruction variants (§3.1), controlling for the known sensitivity of small models to prompt wording.
- **Systematic coverage across both text-only and vision-language settings.** The paper evaluates two tasks (clinical summarization and radiology report generation) and multiple model families (SmolLM2, Gemma-3, LLaMA-3.2, Florence-2, Qwen2.5-VL) with both ICL and PEFT, providing a reasonably broad scope.

## Weaknesses

### Fatal

None. The paper's core data is transparent and the experimental design, while asymmetrical, does not invalidate all findings — properly scoped, the result that a 1B LoRA-tuned model can match/exceed a 7B ICL-only model is still meaningful. The issues are addressable through careful reframing and additional experiments.

### Major

- **Asymmetric comparison invalidates the headline claim.** The paper asserts that "after LoRA fine-tuning, all small LMs outperformed large LMs across every metric" (§4, line 309), and the abstract claims "small models not only reach but occasionally exceed the performance of much larger medical LLMs." However, this rests on comparing **LoRA-fine-tuned small LMs** against **large LMs evaluated only with in-context learning (ICL)**. Figure 3 shows that large LMs (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) have no LoRA bars — only ICL scores. Section 3.2 explicitly states PEFT was applied only "to each small LLM" (line 144). The large models were never fine-tuned on the same data. An apples-to-apples comparison (LoRA-tuned large vs. LoRA-tuned small) is absent, so the paper's central comparative claim is unsupported by its own experimental design. This is not a minor oversight — it is the paper's main thesis.

- **Collapse Analysis metrics are completely undefined.** Table 3 reports Task Adherence (0–1), Hallucination Rate (%), Concept Recall (0–1), Prompt Robustness (0–1), and a composite Readiness Score across the SmolLM2 and Gemma-3 families. Yet Section 3.1 (line 138) provides **no methodology** for any of these — no annotation protocol, no rubric, no description of how hallucinations were detected (automatically or manually), no formula for the composite Readiness Score. The paper presents these as a primary contribution ("Granular 'Collapse' Evaluation," §1 contributions list) but the reader cannot assess what was actually measured. The existence of the table without any methodology means the claimed "safety threshold" at ~1B is an assertion, not a verified finding.

- **Factual error in the radiology results claim.** The paper states that after fine-tuning, "both small VLMs remain below the large VLM baselines in **all metrics**" (line 297) and §5 repeats this (line 327, "fell short of large VLM baselines on all metrics"). However, Table 4 shows that Qwen2.5-VL (3B, fine-tuned) achieves **BERTScore 0.8146**, which exceeds both Med-Flamingo (9B) at 0.7100 and LLaVA-Med v1.5 (7B) at 0.6850. The paper's own data directly contradicts this claim. Finding 2 (§4, line 317) is more cautiously worded ("clinical report quality"), but the explicit "all metrics" statement is wrong.

### Minor

- **Large VLM test-time configuration is unspecified.** The paper compares fine-tuned small VLMs (Florence 2, Qwen2.5-VL) against Med-Flamingo (9B) and LLaVA-Med (7B) in Table 4, but never states whether these large VLMs were used zero-shot, few-shot, or fine-tuned (§3.3). The fine-tuning subsection only describes adapting the small VLMs (lines 282-283). This ambiguity makes the comparison difficult to interpret — particularly because the fine-tuned small models close much of the gap.

- **No variance or statistical significance reported.** All results (Tables 2, 3, 4; Figure 3) are single scalars despite using stochastic decoding (temperature=0.3, top-k=3, top-p=0.9, §3 line 102). With only 250 test samples, the reader cannot assess whether observed differences are reliable.

### Trivial

- Figure 2 caption uses "it's" for "its" and contains a grammatically awkward sentence ("LoRA fine-tuned Llama 3.2 1B model having comparable results on it's counterpart models").

## Nice-to-Haves

- A brief description of MEDCON (beyond citing Yim et al., 2023) would improve self-containedness — e.g., whether concept overlap is computed as precision, recall, or F1.
- Table 4 column is labeled "MedCon" inconsistently with "MEDCON" used elsewhere.

## Removed Points

These points were raised by reviewers but filtered:

- **"Reproducibility concerns about unreleased models/datasets"** — Removed per hard rules: all cited models, datasets, and benchmarks are assumed to exist and be released.
- **"The collapse analysis idea is interesting" (strength)** — Removed because the strength conflicts with the verified weakness that the metrics are undefined. The observation cannot be claimed as a strength without verifiable methodology.
- **"Small VLMs consistently lag behind large VLMs" (strength)** — Removed because the paper's own BERTScore data contradicts "consistently"; Qwen2.5-VL exceeds Med-Flamingo on this metric.
- **Generic strengths ("addresses an important problem," "targets an interesting question")** — Removed as superficial; every paper in a competitive venue addresses an important problem.
- **Missing related work** — Removed per hard rules: the reviewer cannot verify missing references without external confirmation.
- **Formatting and style complaints** — Removed per hard rules; these are parser artifacts, not author errors.

## Novel Insights

None beyond the paper's own contributions. The reviews surface important issues with the experimental design and reporting but do not identify a novel analytical angle that the paper itself misses.

## Suggestions

1. **Reframe the central claim.** Replace "small LMs outperform large LMs" with a precisely scoped statement: e.g., "with LoRA fine-tuning, small LMs (1B) can match or exceed the ICL performance of 7-8B domain-adapted LMs." This is supported by the data and still practically valuable.
2. **Add the missing comparison.** Fine-tune the large LMs (BioMistral-7B, Med-LLaMA-8B, OpenBioLLM-8B) with LoRA on the same data and compare fairly. If this is infeasible, clearly acknowledge the asymmetry as a limitation.
3. **Define the Collapse Analysis methodology.** Provide the annotation protocol, computational method, or rubric for each of Task Adherence, Hallucination Rate, Concept Recall, Prompt Robustness, and the Readiness Score formula.
4. **Correct the factual error.** Revise or qualify the claim that small VLMs lag on "all metrics" to reflect that Qwen2.5-VL's BERTScore exceeds both large VLM baselines.
5. **Specify the large VLM configuration.** State explicitly whether Med-Flamingo and LLaVA-Med were used zero-shot, few-shot, or fine-tuned in Table 4.
6. **Report variance.** Run at least 3 trials with different random seeds and report means ± std or confidence intervals for key tables.
7. **Soften headline scope.** The abstract's opening claim is too broad given the asymmetric comparison. Adjust to match what was actually evaluated.

## Score and Decision

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>